Other Demyelinating Diseases

At MS Australia, we empower researchers to identify ways to treat, prevent and cure MS, seek sustained and systemic policy change via advocacy, and act as the champion for Australia’s community of people affected by MS.

Our ultimate, singular goal is to enable a world without MS.

However, all demyelinating diseases of the central nervous system are important to us. Research across diseases sharing similar features ultimately helps all neurological research in our understanding, management and treatment of demyelinating conditions. Frequently, clinicians and researchers work across both MS and these other demyelinating diseases in tandem. It has partly been intensive research into MS that has helped identify some of the subtle differences between them, leading to researchers and scientists pursuing the possibility that other pathophysiology could be at play, distinct from MS. This has led to the identification of separate disease states such as neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody disorders (MOGAD).

These massive steps forward in the last decade have led to earlier diagnosis of these two diseases and the development of specialised diagnostic tests, diagnostic criteria and treatment options, which will be explored in these pages. With the ultimate aim of improving the quality of life for people with NMOSD and MOGAD, we will continually support research to solve the unanswered questions that still elude us.

Neuromyelitis optica spectrum disorders (NMOSD)
Read More

Newsletter subscription

  • Enter your details

Other Demyelinating Diseases